GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neuronetics Inc (NAS:STIM) » Definitions » Cash Flow from Investing

STIM (Neuronetics) Cash Flow from Investing : $-0.60 Mil (TTM As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Neuronetics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Sep. 2024, Neuronetics spent $0.39 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it received $0.40 Mil from other investing activities. In all, Neuronetics gained $0.01 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Sep. 2024.


Neuronetics Cash Flow from Investing Historical Data

The historical data trend for Neuronetics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuronetics Cash Flow from Investing Chart

Neuronetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial -0.81 -0.73 -9.84 6.73 -1.32

Neuronetics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 -0.56 0.07 -0.12 0.01

Neuronetics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Neuronetics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Neuronetics's Cash Flow from Investing for the quarter that ended in Sep. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuronetics  (NAS:STIM) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Neuronetics's purchase of property, plant, equipment for the three months ended in Sep. 2024 was $-0.39 Mil. It means Neuronetics spent $0.39 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Neuronetics's sale of property, plant, equipment for the three months ended in Sep. 2024 was $0.00 Mil. It means Neuronetics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Neuronetics's purchase of business for the three months ended in Sep. 2024 was $0.00 Mil. It means Neuronetics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Neuronetics's sale of business for the three months ended in Sep. 2024 was $0.00 Mil. It means Neuronetics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Neuronetics's purchase of investment for the three months ended in Sep. 2024 was $0.00 Mil. It means Neuronetics spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Neuronetics's sale of investment for the three months ended in Sep. 2024 was $0.00 Mil. It means Neuronetics gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Neuronetics's net Intangibles purchase and sale for the three months ended in Sep. 2024 was $0.00 Mil. It means Neuronetics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Neuronetics's cash from discontinued investing activities for the three months ended in Sep. 2024 was 0.00 Mil. It means Neuronetics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Neuronetics's cash from other investing activities for the three months ended in Sep. 2024 was $0.40 Mil. It means Neuronetics received $0.40 Mil from other investing activities.


Neuronetics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Neuronetics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuronetics Business Description

Traded in Other Exchanges
Address
3222 Phoenixville Pike, Malvern, PA, USA, 19355
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Executives
Stephen Furlong officer: CFO C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
William Andrew Macan officer: Sr. VP, GC, CCO and Secretary 24275 KATY FREEWAY, SUITE 600, KATY TX 77494
Robert Cascella director C/O HOLOGIC, INC., BEDFORD MA 01730
Glenn P Muir director C/O HOLOGIC, INC., BEDFORD MA 01730
Keith J Sullivan director, officer: President and CEO C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
John K Bakewell director C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NO. BILLERICA MA 01862
Cannell Capital Llc 10 percent owner 245 MERIWETHER CIRCLE, ALTA WY 83414
Joseph H Capper director BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Bruce Joseph Shook director 162 CRICKET AVE, ARDMORE PA 19003
Megan Rosengarten director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Wilfred E Jaeger director C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Gregory Harper officer: VP of Prod. Dev. & Operations C/O NEURONETICS, INC, 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Brian E Farley director 2200 ZANKER ROAD, SUITE F, SAN JOSE CA 95131
Daniel Guthrie officer: Chief Commercial Officer C/O NEURONETICS, INC, 322 PHOENIXVILLE PIKE, MALVERN PA 19355